We have been living with the pandemic for more than a year now. The German biotech industry has developed tests and vaccines in record time. From the industry‘s point of view, what has gone well in the last twelve months and what needs to go better or be improved now in regards of testing, vaccine production and distribution?
Julia Schaft, Managing Director of the BioRN Cluster will discuss these and further questions with her panelists:
- Kai te Kaat, Vice President, Program Management LS, Qiagen
- Edgar Fenzl, Managing Director, FGK Clinical Research
- and Peter Schüßler, Vice President and General Manager, Country Leader Germany Thermo Fisher Scientific
The discussion will take place Thursday 29 April starting 1 pm.